EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Dexamethasone solution and dexamethasone in Mucolox™ for the treatment of oral inflammatory ulcerative diseases: A phase II randomized clinical trial

Michele Lodolo, Burinrutt Thanasuwat iD, Piri Veluppillai, Gus Bassani, Alessandro Villa

Journal of Oral Pathology & Medicine · 2023-10 · 52 (9) · 860-866

DOI: 10.1111/jop.13471 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Oral Pathology & Medicine, online erschienen am 07.08.2023. Verfasst von Michele Lodolo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orofacial Sciences, School of Dentistry, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Dexamethasone, Oral Ulcer, Anti-Inflammatory Agents, Drug Delivery Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Professional Compounding Centers of America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucolox™ is a mucosal drug delivery system that prolongs the contact time between the oral mucosa and topical corticosteroids, potentially reducing the need for multiple applications daily. This study aimed to assess the clinical efficacy and tolerability of dexamethasone 0.5 mg/5 mL solution in Mucolox™ for the management of oral inflammatory ulcerative diseases.

Methods

Participants were randomly assigned to receive dexamethasone 0.5 mg/5 mL in Mucolox™ (Mucolox ™ arm) or dexamethasone 0.5 mg/5 mL solution (standard arm) and instructed to swish/gargle for 5 min three times daily. Changes from pre‐ to posttreatment patient's sensitivity score (0–10 on a visual analog scale), reticulation/erythema/ulceration score, and oral health‐related quality of life were evaluated at baseline and at the end of the study period.

Results

Twenty nine patients (75% females) with a median age of 58 years (range 18–79) were enrolled and randomly allocated to the Mucolox ™ or standard arm. One subject was excluded. Although statistically significant in both arms, the pre‐ to posttreatment sensitivity score reduction was higher in the Mucolox ™ arm (6.3 vs. 4.4‐point reduction). Both arms showed a decrease in the reticulation/erythema/ulceration score between the two visits (7.2 vs. 4.7 [Mucolox ™ arm]; 8.0 vs. 4.8 [standard arm]; p > 0.05). Mucolox™ in dexamethasone 0.5 mg/5 mL solution was better tolerated when taste and level of comfort were considered.

Conclusions

Both treatments were effective in the management of oral inflammatory ulcerative diseases. Dexamethasone 0.5 mg/5 mL in Mucolox™ was better tolerated and was slightly better in controlling patients' oral sensitivity. Larger studies are needed to confirm these findings in oral inflammatory ulcerative diseases patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04540133.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneOral UlcerAnti-Inflammatory AgentsDrug Delivery SystemsHumansFemaleAdultMaleMiddle AgedAdolescentAgedYoung AdultTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

Mucolox™dexamethasone oral solutionoral inflammatory ulcerative diseasestreatment

Substanzen

DexamethasoneAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Orofacial Sciences, School of Dentistry, University of California San Francisco, San Francisco, California, USA.
  • Professional Compounding Centers of America, Houston, Texas, USA.
  • Department of Oral Medicine, Oral Oncology and Dentistry, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.

ORCID-Profile: Burinrutt Thanasuwat

Förderung

  • Professional Compounding Centers of America

Zitieren

APA

Lodolo, M., Thanasuwat, B., Veluppillai, P., Bassani, G., & Villa, A. (2023). Dexamethasone solution and dexamethasone in Mucolox™ for the treatment of oral inflammatory ulcerative diseases: A phase II randomized clinical trial. Journal of Oral Pathology & Medicine, 52(9), 860-866. https://doi.org/10.1111/jop.13471

Vancouver

Lodolo M, Thanasuwat B, Veluppillai P, Bassani G, Villa A. Dexamethasone solution and dexamethasone in Mucolox™ for the treatment of oral inflammatory ulcerative diseases: A phase II randomized clinical trial. Journal of Oral Pathology & Medicine. 2023;52(9):860-866. doi:10.1111/jop.13471

BibTeX
@article{Lodolo2023,
  author = {Lodolo, Michele and Thanasuwat, Burinrutt and Veluppillai, Piri and Bassani, Gus and Villa, Alessandro},
  title = {Dexamethasone solution and dexamethasone in Mucolox™ for the treatment of oral inflammatory ulcerative diseases: A phase II randomized clinical trial},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2023},
  volume = {52},
  number = {9},
  pages = {860--866},
  doi = {10.1111/jop.13471}
}
Kostenlos starten →